Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by POULAIN, P.
Right arrow Articles by AHERNE, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by POULAIN, P.
Right arrow Articles by AHERNE, G. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 1988, Vol. 61, No. 5 569-574
© 1988 The Board of Management and Trustees of the British Journal of Anaesthesia

research-article

RELATIVE BIOAVAILABILITY OF CONTROLLED RELEASE MORPHINE TABLETS (MST CONTINUS) IN CANCER PATIENTS

P. POULAIN, M.D.*,, P. J. HOSKIN, B.SC., M.B., M.R.C.P., F.R.C.R., G. W. HANKS, B.SC., M.B., M.R.C.P., O. A-OMAR, B. PHARM., V. A. WALKER, B.SC., R.G.N.**,, A. JOHNSTON, B.SC., P. TURNER, B.SC., M.D., F.R.C.P. and G. W. AHERNE, B.SC, PH.D.

Continuing Care Unit, Royal Marsden Hospital Fulham Road, London SW3 6JJ
Department of Clinical Pharmacology, St Bartholomew's Hospital Medical College London
Department of Biochemistry, University of Surrey Guildford, Surrey

Correspondence to G. W. Hanks.

The bioavailability of oral controlled release morphine tablets (MST, Napp Laboratories) and oral morphine sulphate in aqueous solution (MSS) was compared in 10 patients with advanced cancer. Serum samples were analysed for morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) using a specific HPLC assay. The relative bioavailability of morphine with MST was significantly less than that with MSS (mean 80%, range 50–110%) although there was no difference between the formulations in the relative availability of M3G and M6G. There was no significant difference between the formulations in the serum concentration of morphine at 12 h. The mean ratios morphine: M6G: M3G (comparing areas under the serum concentration-time curves) were 1:9:56. There was a highly significant linear relationship between the dose administered and AUC for morphine, M3G and M6G after MSS; and for morphine after MST. Median tmax for morphine was 0.5 h with MSS and 2.5h with MST; for M3G 1.5h with MSS and 3.0h with MST; and for M6G 1.5h with MSS and 3.25h with MST. A secondary peak of unconjugated morphine, which may represent enterohepatic circulation, was seen in several patients 2–4h after administration of elixir and 4–6 h after administration of MST.

*Institut Gustave-Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France.

**Leeds General Infirmary, Leeds LS1 3EX.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Palliat MedHome page
G Andersen, N-H Jensen, L Christrup, S H Hansen, and P Sjogren
Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine
Palliative Medicine, March 1, 2002; 16(2): 107 - 114.
[Abstract] [PDF]

Home page
 BMJHome page
Fortnightly Review: Morphine in cancer pain: modes of administration
BMJ, March 30, 1996; 312(7034): 823 - 826.
[Full Text]

Home page
 Palliat MedHome page
D. Gorman
Review article : Opioid analgesics in the management of pain in patients with cancer: an update
Palliative Medicine, October 1, 1991; 5(4): 277 - 294.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.